Target intelligence / Profile preview

D-alanyl-D-alanine terminus of peptidoglycan precursor unit

Molecular classification
Other (peptidoglycan terminus/antibiotic-binding site)
01

Overview

The D-alanyl-D-alanine terminus of peptidoglycan precursor units is a highly conserved dipeptide that constitutes the terminal amino acids of the peptide sidechain in the nascent peptidoglycan subunits (often on a MurNAc sugar via a pentapeptide stem). This terminus serves as the primary substrate for bacterial transpeptidase enzymes (penicillin-binding proteins) that catalyze the crosslinking of peptidoglycan strands, an essential step in bacterial cell wall biosynthesis[2][3][4][5]. Glycopeptide antibiotics such as vancomycin target this terminus by forming stable non-covalent interactions, thereby preventing proper cell wall assembly, which is lethal to bacteria. Bacterial resistance often develops via substitution of the D-alanyl-D-alanine terminus with alternative structures such as D-alanyl-D-lactate, which reduces antibiotic binding and confers resistance[1][8]. This target is critical for the mechanism of several clinically important antibiotics and is a major determinant in the efficacy and resistance profile of these agents.

Other names
D-Ala-D-Ala terminusD-ala-D-ala moietyD-alanyl-D-alanine endterminal D-alanyl-D-alanineD-alanyl-D-alanine of peptidoglycan precursor
02

Mechanism of action

Glycopeptide antibiotics (e.g., vancomycin) bind to the D-alanyl-D-alanine terminus, sterically blocking the action of transpeptidase and transglycosylase enzymes, thus inhibiting crosslinking and elongation of the peptidoglycan, leading to bactericidal cell death[1][8].

03

Biological functions

Bacterial cell wall synthesisSubstrate for transpeptidation (crosslinking of peptidoglycan)
04

Disease associations

Infection (antibiotic target, notably for resistant bacteria)
05

Safety considerations

Therapeutic challenge: resistance mediated by replacement of D-alanyl-D-alanine with D-alanyl-D-lactate or D-alanyl-D-serine, conferring reduced antibiotic binding affinity[1][8].No direct human safety risks, but resistance emergence threatens antibiotic utility.
06

Interacting drugs

Vancomycin

5 more in the full profile.

Beyond the preview

Go deeper on D-alanyl-D-alanine terminus of peptidoglycan precursor unit.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on D-alanyl-D-alanine terminus of peptidoglycan precursor unit.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call